Related Experiment Videos

Effect of fixed-dose losartan/hydrochlorothiazide on brain natriuretic peptide in patients with hypertension

Yuhei Shiga1, Shin-ichiro Miura, Ryoko Mitsutake

  • 1Department of Cardiology, Fukuoka University School of Medicine, Jonan-ku, Fukuoka, Japan. miuras@cis.fukuoka-u.ac.jp

Journal of the Renin-Angiotensin-Aldosterone System : JRAAS
|July 13, 2011
PubMed

Insights

Losartan/hydrochlorothiazide significantly lowered blood pressure and brain natriuretic peptide (BNP) levels in hypertensive patients. This combination therapy may offer cardioprotective benefits, particularly for those with elevated BNP.

Area of Science:

  • Cardiology
  • Pharmacology
  • Hypertension Management

Background:

  • Losartan/hydrochlorothiazide (HCTZ) is a potent fixed-dose combination therapy for hypertension.
  • The relationship between losartan/HCTZ and brain natriuretic peptide (BNP) levels requires further investigation.

Purpose of the Study:

  • To evaluate the effect of switching from an angiotensin II receptor blocker (ARB) to losartan/HCTZ on blood pressure and plasma BNP levels.
  • To explore potential cardioprotective effects of losartan/HCTZ therapy.

Main Methods:

  • A study involving 44 hypertensive patients inadequately controlled on ARB therapy.
  • Patients were switched to losartan/HCTZ, with analysis of blood pressure, pulse rate, and plasma BNP levels at baseline and 6 and 12 months.

Main Results:

  • 75% of patients achieved target blood pressure at 12 months, with significant reductions in systolic and diastolic pressure.
  • Plasma BNP levels significantly decreased during the study period, particularly in patients with higher baseline BNP.
  • No significant changes were observed in pulse rate or other biochemical parameters.

Conclusions:

  • Losartan/HCTZ therapy effectively reduces blood pressure and plasma BNP levels in hypertensive patients.
  • The observed reduction in BNP suggests potential cardioprotective effects of losartan/HCTZ, especially in individuals with elevated BNP.
Abstract

Related Concept Videos

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors01:30

Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors

Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
Antihypertensive Drugs: Angiotensin II Receptor Blockers01:30

Antihypertensive Drugs: Angiotensin II Receptor Blockers

In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
Antihypertensive Drugs: Direct Renin Inhibitors01:25

Antihypertensive Drugs: Direct Renin Inhibitors

The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
Antihypertensive Drugs: Action of β1 Blockers01:17

Antihypertensive Drugs: Action of β1 Blockers

β1-receptors are primarily located in the heart and kidneys. In cardiac myocytes, these receptors interact with neurotransmitters released by the sympathetic nervous system during heightened activity or danger. As a result, β1-receptors get activated, initiating a series of biochemical processes. Excessive activation of beta receptors due to chronic stress can abnormally increase heart rate and contractility, resulting in high blood pressure or hypertension. To counteract this, β1-blockers...
Hypertension II: Pathophysiology01:29

Hypertension II: Pathophysiology

Hypertension is a chronic condition in which the blood's force against artery walls is excessively high, posing risks such as heart disease. The condition's underlying mechanisms involve complex interactions among the cardiovascular, kidney, and autonomic nervous systems.Renin-Angiotensin-Aldosterone System (RAAS): This system significantly influences blood pressure regulation. When blood pressure decreases, the kidneys secrete renin. This enzyme transforms angiotensinogen, a plasma protein,...